Innoveren Scientific Inc.

PINK:IVRN USA Biotechnology
Market Cap
$932.48
Market Cap Rank
#49956 Global
#15249 in USA
Share Price
$0.00
Change (1 day)
+0.00%
52-Week Range
$0.00 - $0.00
All Time High
$1.50
About

Innoveren Scientific Inc., a medical bioscience company that develops technology in regenerative medicine for limb salvage. It is also developing immunotherapies for ovarian cancer, pancreatic cancer, and mesothelioma. The company was formerly known as H-CYTE, Inc. and changed its name to Innoveren Scientific Inc. in July 2023. The company is headquartered in Tampa, Florida.

Market Cap & Net Worth: Innoveren Scientific Inc. (IVRN)

Innoveren Scientific Inc. (PINK:IVRN) has a market capitalization of $932.48 ($932.48) as of March 19, 2026. Listed on the PINK stock exchange, this USA-based company holds position #49956 globally and #15249 in its home market, demonstrating a 0.00% increase in market value over the past year.

Market capitalization, also known as net worth in stock markets, is calculated by multiplying Innoveren Scientific Inc.'s stock price $0.00 by its total outstanding shares 4662421 (4.66 Million).

Innoveren Scientific Inc. Market Cap History: 2023 to 2025

Innoveren Scientific Inc.'s market capitalization history from 2023 to 2025. Data shows change from $540.84K to $932.48 (-99.23% CAGR).

Innoveren Scientific Inc. Market Cap to Earnings & Revenue Ratios Timeline

This chart shows how Innoveren Scientific Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.

Latest Price to Sales (P/S) Ratio

No P/S ratio data available

Latest Price to Earnings (P/E) Ratio

No P/E ratio data available

What These Ratios Tell Investors:
  • Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
  • Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
  • Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
  • Industry comparison provides context for whether the company is valued higher or lower than peers.
Year Market Cap (USD) Revenue (USD) Net Income (USD) P/S Ratio P/E Ratio
No financial ratio data available

Competitor Companies of IVRN by Market Capitalization

Companies near Innoveren Scientific Inc. in the global market cap rankings as of March 19, 2026.

Key companies related to Innoveren Scientific Inc. by market ranking:

  • Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
  • Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
  • CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
  • argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.

Market capitalization comparison (in billions USD)
Rank Company Symbol Market Cap Price
#162 Vertex Pharmaceuticals Inc NASDAQ:VRTX $117.09 Billion $462.49
#281 Regeneron Pharmaceuticals Inc NASDAQ:REGN $74.80 Billion $759.05
#344 CSL Limited PINK:CMXHF $63.46 Billion $149.87
#500 argenx SE OTCGREY:ARGNF $42.99 Billion $697.42

Innoveren Scientific Inc. Historical Marketcap From 2023 to 2025

Between 2023 and today, Innoveren Scientific Inc.'s market cap moved from $540.84K to $ 932.48, with a yearly change of -99.23%.

Year Market Cap Change (%)
2025 $932.48 -99.83%
2023 $540.84K --

End of Day Market Cap According to Different Sources

On Mar 18th, 2026 the market cap of Innoveren Scientific Inc. was reported to be:

Source Market Cap
Yahoo Finance $932.48 USD
MoneyControl $932.48 USD
MarketWatch $932.48 USD
marketcap.company $932.48 USD
Reuters $932.48 USD

Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.